Ardelyx (ARDX) Expected to Announce Quarterly Earnings on Thursday

Ardelyx (NASDAQ:ARDX) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.05) per share and revenue of $121.6710 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Ardelyx Trading Up 0.6%

Shares of ARDX opened at $4.98 on Tuesday. Ardelyx has a twelve month low of $4.24 and a twelve month high of $8.40. The company has a market cap of $1.23 billion, a P/E ratio of -21.65 and a beta of 0.70. The company has a current ratio of 3.49, a quick ratio of 3.28 and a debt-to-equity ratio of 1.37. The company’s fifty day simple moving average is $5.49 and its 200-day simple moving average is $6.13.

Wall Street Analysts Forecast Growth

ARDX has been the subject of a number of recent analyst reports. LADENBURG THALM/SH SH initiated coverage on shares of Ardelyx in a research note on Tuesday, June 16th. They set a “buy” rating and a $16.00 price target for the company. Zacks Research lowered shares of Ardelyx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Finally, Weiss Ratings downgraded shares of Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.73.

Insiders Place Their Bets

In other news, insider Mike Kelliher sold 7,248 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the sale, the insider directly owned 357,418 shares of the company’s stock, valued at approximately $2,241,010.86. The trade was a 1.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Duane Foster sold 7,998 shares of Ardelyx stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $50,147.46. Following the sale, the insider owned 417,972 shares of the company’s stock, valued at $2,620,684.44. The trade was a 1.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 24,572 shares of company stock valued at $154,066 over the last three months. Insiders own 5.30% of the company’s stock.

Institutional Trading of Ardelyx

Several institutional investors and hedge funds have recently modified their holdings of the stock. State of Wyoming bought a new position in Ardelyx in the fourth quarter worth approximately $74,000. WINTON GROUP Ltd bought a new stake in Ardelyx during the 4th quarter valued at $79,000. Jain Global LLC bought a new stake in Ardelyx during the 3rd quarter valued at $74,000. Sargent Investment Group LLC purchased a new stake in shares of Ardelyx in the 4th quarter worth $82,000. Finally, Steward Partners Investment Advisory LLC grew its position in shares of Ardelyx by 81.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 14,021 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 6,293 shares in the last quarter. Institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.